PT  - JOURNAL ARTICLE
AU  - Ogasahara, Saburo
AU  - Nishikawa, Yoshiro
AU  - Yorifuji, Shiro
AU  - Soga, Fumihisa
AU  - Nakamura, Yusaku
AU  - Takahashi, Mitsuo
AU  - Hashimoto, Shigeo
AU  - Kono, Norio
AU  - Tarui, Seiichiro
TI  - Treatment of Kearns‐Sayre syndrome with coenzyme Q<sub>10</sub>
AID  - 10.1212/WNL.36.1.45
DP  - 1986 Jan 01
TA  - Neurology
PG  - 45--45
VI  - 36
IP  - 1
4099  - http://n.neurology.org/content/36/1/45.short
4100  - http://n.neurology.org/content/36/1/45.full
SO  - Neurology1986 Jan 01; 36
AB  - We studied the metabolism of coenzyme Q10 (CoQ) and the effects of CoQ therapy in five patients with Kearns-Sayre syndrome (KSS). Although the mitochondrial fraction was increased in muscles from KSS patients, CoQ content was slightly low. CoQ synthesis was normal in fibroblasts from KSS patients. Administration of 120 to 150 mg/d of CoQ improved abnormal metabolism of pyruvate and NADH oxidation in skeletal muscle. CoQ therapy decreased CSF protein concentration and CSF lactate/pyruvate ratio. ECG abnormalities and neurologic symptoms also improved.